Light AI Inc.

Light AI Inc. is a healthcare technology company based in Vancouver, British Columbia, Canada, specializing in the development of artificial intelligence and machine learning diagnostic digital healthcare solutions. The company's mission is to deliver relevant solutions for the global healthcare community by leveraging assistive AI to enhance diagnostic methods through a cost-effective, scalable platform, empowering healthcare providers to better prevent, diagnose, and manage infectious diseases.

Light AI's primary product is the Light.AI technology platform, which utilizes software as a medical device to automatically diagnose Group A Streptococcus (Strep A) infections. This app-based solution is designed to operate on compatible smart devices, such as smartphones, eliminating the need for traditional swabs, lab tests, or proprietary hardware. The company aims to address critical healthcare challenges, including antimicrobial resistance, by providing rapid, accurate, and cost-effective screening and diagnostic tools, with plans to expand its AI applications to other medical conditions like throat, eye, and skin ailments.

Recent developments for Light AI Inc. include the closing of a C$5,000,000 secured convertible debenture unit financing in June 2026 and the initiation of an FDA pivotal clinical trial for its QuickScan™ Strep A Software as a Medical Device (SaMD). The company also announced a field study for its QuickScan™ platform in New Zealand and appointed Dallas Fontaine to its board of directors in June 2026. Led by CEO John R. Luna and Founder Peter Douglas Whitehead, Light AI is positioned as an innovator in AI-powered health diagnostics, though it is currently pre-revenue.